Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ivanov, Mikhail
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	464	Europe, US, RoW	SEP-363856 75mg, SEP-363856 100mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	06/23	06/23
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia	Terminated	3	463	Europe, US, RoW	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	11/23	11/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ivanov, Mikhail
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	464	Europe, US, RoW	SEP-363856 75mg, SEP-363856 100mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	06/23	06/23
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia	Terminated	3	463	Europe, US, RoW	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	11/23	11/23